Abstract #0567

Characterization of Gd-DOTA-APC, a novel cancer-targeting MRI contrast agent

Christina Brunnquell¹, Ray Zhang², Benjamin Cox^1,3, Anatoly Pinchuk², Alan McMillan², and Jamey Weichert²

¹Medical Physics, University of Wisconsin-Madison, Madison, WI, United States, ²Radiology, University of Wisconsin-Madison, Madison, WI, United States, ³Medical Engineering Group, Morgridge Institute for Research, Madison, WI, United States

In this work we characterize the relaxivity, chemical stability, and tumor-specific uptake of a cancer-targeting T₁-shortening contrast agent, Gd-DOTA-APC. We observe striking longitudinal relaxivity of up to 16.5 s^-1/mM and 10.6 s^-1/mM at 1.5T and 3.0T, respectively. High chemical stability was measured, with less than 0.1% free Gd³⁺ detected after dissolution of the agent in buffer. Finally, we observe tumor-specific T₁-weighted signal enhancement following Gd-DOTA-APC delivery, sustained out to seven days after administration. These observations indicate that Gd-DOTA-APC holds potential as a safe and effective agent for targeted cancer imaging.

This abstract and the presentation materials are available to members only; a login is required.

Join Here